The US administration will levy up to 200% tariffs on generic medicine imports starting August 2028 to boost local manufacturing. This policy creates significant pressure for Indian pharmaceutical exporters, who currently supply nearly half of the generic prescriptions in the US market. Investors should monitor how firms manage costs and potential shifts in global production.
Detailed Coverage
The United States administration has announced a plan to impose duties of up to 200% on imported generic medicines, effective August 2028. This policy is designed to encourage companies to move their manufacturing operations within US borders, providing a two-year window for businesses to adjust their supply chains.
Impact on India’s Pharmaceutical Exports
India serves as a critical supplier for the American healthcare system, contributing roughly 47% of all generic prescriptions dispensed in the country. Official data indicates that Indian pharmaceutical exports to the US totaled $9.7 billion in 2025, accounting for 37.7% of India's total global drug exports. While the US is India's largest overseas market, Indian generic drugs are often priced significantly lower than local branded alternatives. Because of this large price difference, industry observers note that some products may remain cost-competitive even after accounting for higher duties, potentially shifting the financial burden onto US insurers and healthcare providers.
Manufacturing and Strategic Challenges
Many prominent Indian companies, such as Sun Pharma, Dr. Reddy’s Laboratories, Aurobindo Pharma, Lupin, Cipla, and Zydus Lifesciences, already possess FDA-approved manufacturing plants within the United States. While these facilities provide a buffer, expanding them to meet higher domestic demand requires massive capital investment and carries risks related to higher operational costs.
Beyond the tariff threat, the sector faces a structural dependency issue. Indian manufacturers rely on China for approximately 70% of their chemical-based active pharmaceutical ingredients and nearly 90% of biological inputs. This concentration creates a secondary risk where supply chain disruptions in China could complicate the transition toward more localized manufacturing.
Investor Monitorables
Investors may track how Indian pharmaceutical firms adapt their US strategies over the next two years. Key areas to watch include management commentary on capital spending plans for US-based manufacturing, the potential for price adjustments to offset new duties, and efforts to diversify exports to other regions like Europe, Latin America, and Africa. Additionally, the progress of government-led initiatives to strengthen India’s domestic API production will be a major long-term indicator for the stability of profit margins in this sector.